Wuxi Bio (02269) is currently up more than 4%, and as of press time, it has risen 3.7% to HK$11.78 with a turnover of 0.27 billion Hong Kong dollars.
According to the Wise News APP, Wuxi Bio (02269) is currently up more than 4%, and as of press time, it has risen 3.7% to HK$11.78 with a turnover of 0.27 billion Hong Kong dollars.
On July 5th, the executive meeting of the State Council reviewed and passed the "Full Chain Support Program for Innovative Drug Development." Subsequently, Shanghai issued the "Opinions on Supporting the Innovative Development of the Biomedical Industry in the Full Chain." Prior to this, Beijing, Guangzhou, Zhuhai and other places have already introduced measures to support high-quality development of the pharmaceutical industry throughout the whole chain. Industry insiders say that as policies are gradually implemented, the environment for innovative drugs is expected to gradually improve from financing to research and development and application promotion.
Southwest Securities pointed out that from a macro perspective, based on current economic data, the expectation of the Fed's interest rate cut this year is increasing, the first-level investment and financing environment of biomedical industry may improve, the market liquidity expectation is restored, and there will be valuation repair opportunities in the innovative drug industry chain; the top CXO new crown commercial orders have been fully digested, and the geo-strategic game is yet to be landed; the sector valuation has fallen to its historical bottom, but stock valuation is still showing differentiation. From the industry perspective, global pharmaceutical research and development investment is steadily increasing, and the CXO industry's business outlook still fluctuates.